Amgen

MVASI

Manufacturer:

Amgen

Mvasi HCPCS:

Q5107

HCPCS Code Descriptor:

Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg

Category:

Q Code

Mvasi NDCs:

55513-0206-01, 55513-0207-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Mvasi:

MVASI is an Oncology Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5107 is aligned to the drug MVASI.

Mvasi (bevacizumab) is a cancer drug that blocks the VEGF protein. This medication is used to treat certain cancers of the brain, kidney, liver, lung, colon, rectum, cervix, ovary, or Fallopian tube. Mvasi can also be used to treat specific cancers that affect the membrane lining of the patient’s internal organs. This medication is manufactured by Amgen USA and is biosimilar to Avastin (J9035). Mvasi only has one HCPCS code, Q5107 that was aligned to the medication January 2019. Patient assistance programs for this durg can be found through the Amgen Safety Net Foundation and the Amgen Support Plus program.

ACCESS PRICING AND MORE BY REGISTERING

Q5107 Added Date:

January 1, 2019

Q5107 Effective Date:

January 1, 2019

Q5107 Termination Date:

HCPCS Active

Mvasi billing and coding information can be found through Amgen at the link below:
Mvasi patient assistance information can be found through Amgen’s Amgen Safety Net Foundation at the URL: http://www.amgensafetynetfoundation.com
MVASI prescribing information can be found at the link below:
Information regarding MVASI’s side effects can be found at MedlinePlus